Benefits of GLP-1 Mimetics on Epicardial Adiposity

The epicardial adipose tissue, which is referred to as fats surrounding the myocardium, is an active organ able to induce cardiovascular problems in pathophysiologic conditions through several pathways, such as inflammation, fibrosis, fat infiltration, and electrophysiologic problems. So, control of its volume and thickness, especially in patients with diabetes, is highly important. Incretin-based pharmacologic agents are newly developed antidiabetics that could provide further cardiovascular benefits through control and modulating epicardial adiposity. They can reduce cardiovascular risks by rapidly reducing epicardial adipose tissues, improving cardiac efficiency. We are at the first steps of a long way, but current evidence demonstrates the sum of possible mechanisms. In this study, we evaluate epicardial adiposity in physiologic and pathologic states and the impact of incretin-based drugs.

Automated summary

The epicardial adipose tissue, known as the adipose tissue surrounding the myocardium, can cause cardiovascular problems through various mechanisms. Controlling its volume and thickness, especially in diabetic patients, is crucial. Incretin-based drugs, as newly developed antidiabetics, have the potential to reduce cardiovascular risks by regulating epicardial adiposity. This study aims to evaluate the impact of incretin-based drugs on both physiological and pathological epicardial adiposity.